They employed 75 representatives for Nextellis.
Trained them for 3-4 months prior to FDA
approval to sell. The expected Sales and
Marketing cost projection was $75m.
Now this financial year outlook sales revenue
for Nextellis approximately $20m. Even our
CEO ( new) said should the entire sales staff
average the same as the top three T/O would
be 2 and 1/2 times higher. Either the product is
not being readily taken up or sales staff are just
order takers. The Royalty Revenue stream deal
done by TherapeuticsMD with Mayne under the
situation they were in is extraordinary. An incredably
good deal on their behalf.
- Forums
- ASX - By Stock
- MYX
- Ann: MYX signs license agreement for women's health products
Ann: MYX signs license agreement for women's health products, page-102
-
- There are more pages in this discussion • 96 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MYX (ASX) to my watchlist
(20min delay)
|
|||||
Last
$4.38 |
Change
-0.020(0.45%) |
Mkt cap ! $369.2M |
Open | High | Low | Value | Volume |
$4.42 | $4.45 | $4.23 | $687.0K | 158.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 2249 | $4.37 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.38 | 13 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 1365 | 4.340 |
9 | 9818 | 4.330 |
7 | 2301 | 4.320 |
5 | 2657 | 4.310 |
4 | 4405 | 4.300 |
Price($) | Vol. | No. |
---|---|---|
4.360 | 602 | 2 |
4.370 | 2498 | 7 |
4.380 | 876 | 6 |
4.390 | 976 | 6 |
4.400 | 564 | 3 |
Last trade - 15.13pm 15/07/2024 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online